Gujarat Themis Biosyn Ltd (GUJTHEM) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 925632,
    "name": "Guj. Themis Bio.",
    "stock_name": "Guj. Themis Bio.",
    "full_name": "Gujarat Themis Biosyn Ltd",
    "name_url": "stocks-analysis/guj-themis-bio",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "328.85",
    "chg": 9.55,
    "chgp": "2.99%",
    "dir": 1,
    "prev_price": "319.30",
    "mcapval": "3,583.32 Cr",
    "mcap": "Small Cap",
    "scripcode": 506879,
    "symbol": "GUJTHEM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE942C01045",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "45.81 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/guj-themis-bio-925632-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Guj. Themis Bio. Sees Revision in Market Assessment Amid Valuation and Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/guj-themis-bio-downgraded-to-hold-by-marketsmojo-amid-valuation-concerns-3735226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujThemisBio_mojoScore_3735226.png",
        "date": "2025-11-28 10:05:12",
        "description": "Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. This adjustment highlights evolving perspectives on the company’s valuation, financial trends, quality metrics, and technical outlook amid a backdrop of mixed performance indicators."
      },
      {
        "title": "Gujarat Themis Biosyn Sees Shift in Technical Momentum Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gujarat-themis-biosyn-sees-technical-momentum-shift-amid-mixed-market-signals-3719725",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratThemisBi_technicaldot_3719725.png",
        "date": "2025-11-21 08:07:35",
        "description": "Gujarat Themis Biosyn, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across various timeframes. Recent market data reveals a mild adjustment in the company’s technical parameters, coinciding with a day change of -3.73% and a current price of ₹420.75, down from the previous close of ₹437.05."
      },
      {
        "title": "Why is Guj. Themis Bio. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-guj-themis-bio-fallingrising-3719259",
        "imagepath": "",
        "date": "2025-11-21 00:36:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Context</strong></p>\n<p>The stock’s decline on 20-Nov was marked by an intraday low of ₹420, representing a 3.9% drop from previous levels. This underperformance was also evident when compared to its sector peers, with Gujarat Themis Biosyn lagging by 3.47% relative to the sector’s gains on the same day. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, suggesting selling pressure dominated trading activity.</p>\n<p>Further technical analysis reveals that while the stock remains above its 100-day and 200-day moving averages, it is currently trading below its 5-day, 20-day, and 50-day moving averages. This pattern often signals short-term weakness or consolidation after recent gains, as investors reassess va..."
      },
      {
        "title": "How has been the historical performance of Guj. Themis Bio.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-guj-themis-bio-3694048",
        "imagepath": "",
        "date": "2025-11-12 23:18:30",
        "description": "Answer:\nThe historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years.\n\nBreakdown:\nGuj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'..."
      },
      {
        "title": "Are Guj. Themis Bio. latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-guj-themis-bio-latest-results-good-or-bad-3690488",
        "imagepath": "",
        "date": "2025-11-11 19:35:27",
        "description": "Gujarat Themis Biosyn's latest financial results for Q2 FY26 highlight a notable performance across several key metrics. The company reported net sales of ₹42.35 crores, reflecting an 18.07% quarter-on-quarter growth and a robust 21.98% increase year-on-year. This marks the highest quarterly sales figure in the company's recent history. The operating profit margin, excluding other income, reached a record 49.47%, indicating strong cost management and pricing power.\n\nNet profit for the quarter stood at ₹14.26 crores, which represents a significant 57.40% increase compared to the previous quarter. The net profit margin improved to 33.67%, showcasing effective operational leverage and tax management. These results are particularly impressive given the broader challenges faced by the pharmaceutical sector, which has seen negative returns over the past year.\n\nThe company also demonstrated exceptional capital eff..."
      },
      {
        "title": "Gujarat Themis Biosyn Reports Significant Financial Improvements and Market Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gujarat-themis-biosyns-financial-trend-shifts-from-negative-to-positive-with-strong-performance-3687903",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratThemisBi_fintrenddot_3687903.png",
        "date": "2025-11-11 08:00:23",
        "description": "Gujarat Themis Biosyn has reported significant financial improvements for the quarter ending September 2025, achieving record net sales of Rs 42.35 crore and a PBDIT of Rs 20.95 crore. The company also demonstrated strong operational efficiency with a 49.47% operating profit margin and impressive profitability metrics."
      },
      {
        "title": "Gujarat Themis Biosyn Q2 FY26: Stellar Quarter Pushes Stock to New Heights",
        "link": "https://www.marketsmojo.com/news/result-analysis/gujarat-themis-biosyn-q2-fy26-stellar-quarter-pushes-stock-to-new-heights-3686716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GujaratThemisBi_quaterlyResult_3686716.png",
        "date": "2025-11-10 18:06:28",
        "description": "Gujarat Themis Biosyn Ltd., a Vapi-based pharmaceutical manufacturer, delivered an exceptional performance in Q2 FY26, posting net profit of ₹14.26 crores—a 34.92% quarter-on-quarter surge and 21.98% year-on-year growth. The company's shares have responded enthusiastically, trading at ₹454.25 as of November 10, representing a 0.89% single-day gain and maintaining a commanding 40.20% annual return despite the stock's premium valuation of 111 times trailing earnings."
      }
    ],
    "total": 335,
    "sid": "925632",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/gujarat-themis-biosyn-925632"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "31-Jan-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on January 30 2026 for Themis Medicare Ltd",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Approval Of Financial Results For The Quarter And Nine Months Ended 31St December 2025",
      "datetime": "30-Jan-2026",
      "details": "Gujarat Themis Biosyn Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 inter alia to consider and approve Please refer to the attachment.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "20-Jan-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on January 19 2026 for Themis Medicare Ltd",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Gujarat Themis Biosyn Ltd has declared <strong>67%</strong> dividend, ex-date: 04 Sep 25",
          "dt": "2025-09-04",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Gujarat Themis Biosyn Ltd has announced <strong>1:5</strong> stock split, ex-date: 10 Oct 23",
          "dt": "2023-10-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Gujarat Themis Biosyn Ltd has announced <strong>1:2</strong> bonus issue, ex-date: 09 Aug 24",
          "dt": "2024-08-09",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Guj. Themis Bio. Sees Revision in Market Assessment Amid Valuation and Financial Trends

2025-11-28 10:05:12

Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. This adjustment highlights evolving perspectives on the company’s valuation, financial trends, quality metrics, and technical outlook amid a backdrop of mixed performance indicators.

Gujarat Themis Biosyn Sees Shift in Technical Momentum Amid Mixed Market Signals

2025-11-21 08:07:35

Gujarat Themis Biosyn, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across various timeframes. Recent market data reveals a mild adjustment in the company’s technical parameters, coinciding with a day change of -3.73% and a current price of ₹420.75, down from the previous close of ₹437.05.

Why is Guj. Themis Bio. falling/rising?

2025-11-21 00:36:50

Short-Term Price Movement and Market Context The stock’s decline on 20-Nov was marked by an intraday low of ₹420, representing a 3.9% drop from previous levels. This underperformance was also evident when compared to its sector peers, with Gujarat Themis Biosyn lagging by 3.47% relative to the sector’s gains on the same day. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, suggesting selling pressure dominated trading activity. Further technical analysis reveals that while the stock remains above its 100-day and 200-day moving averages, it is currently trading below its 5-day, 20-day, and 50-day moving averages. This pattern often signals short-term weakness or consolidation after recent gains, as investors reassess va...

How has been the historical performance of Guj. Themis Bio.?

2025-11-12 23:18:30

Answer: The historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years. Breakdown: Guj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'...

Are Guj. Themis Bio. latest results good or bad?

2025-11-11 19:35:27

Gujarat Themis Biosyn's latest financial results for Q2 FY26 highlight a notable performance across several key metrics. The company reported net sales of ₹42.35 crores, reflecting an 18.07% quarter-on-quarter growth and a robust 21.98% increase year-on-year. This marks the highest quarterly sales figure in the company's recent history. The operating profit margin, excluding other income, reached a record 49.47%, indicating strong cost management and pricing power. Net profit for the quarter stood at ₹14.26 crores, which represents a significant 57.40% increase compared to the previous quarter. The net profit margin improved to 33.67%, showcasing effective operational leverage and tax management. These results are particularly impressive given the broader challenges faced by the pharmaceutical sector, which has seen negative returns over the past year. The company also demonstrated exceptional capital eff...

Gujarat Themis Biosyn Reports Significant Financial Improvements and Market Outperformance

2025-11-11 08:00:23

Gujarat Themis Biosyn has reported significant financial improvements for the quarter ending September 2025, achieving record net sales of Rs 42.35 crore and a PBDIT of Rs 20.95 crore. The company also demonstrated strong operational efficiency with a 49.47% operating profit margin and impressive profitability metrics.

Gujarat Themis Biosyn Q2 FY26: Stellar Quarter Pushes Stock to New Heights

2025-11-10 18:06:28

Gujarat Themis Biosyn Ltd., a Vapi-based pharmaceutical manufacturer, delivered an exceptional performance in Q2 FY26, posting net profit of ₹14.26 crores—a 34.92% quarter-on-quarter surge and 21.98% year-on-year growth. The company's shares have responded enthusiastically, trading at ₹454.25 as of November 10, representing a 0.89% single-day gain and maintaining a commanding 40.20% annual return despite the stock's premium valuation of 111 times trailing earnings.

View All News